SCHEMBL20162798

SCHEMBL20162798

FC(F)(F)c1ncc(-c2ncc3cc[nH]c3n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 2/20 0.41
ALOX5AP P20292 1/20 0.41
CDK8 P49336 7/20 0.37
AXL P30530 2/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
NUDT1 P36639 2/20 0.36
RIPK1 Q13546 3/20 0.36
ULK1 O75385 3/20 0.33
CDK7 P50613 2/20 0.33
CCNT1 O60563 1/20 0.33
CCND1 P24385 1/20 0.33
CCNC P24863 1/20 0.33
CDK9 P50750 1/20 0.33
CCNH P51946 1/20 0.33
MNAT1 P51948 1/20 0.33
CDK6 Q00534 1/20 0.33
PLK4 O00444 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22264422 0.83 AXL (0.38) FEN1ALOX5APCDK8AXLPIK3CD
SCHEMBL20162766 0.77 DHFR (0.37) PIK3CANUDT1RIPK1ULK1CCNT1
SCHEMBL17065188 0.76 MAPK1 (0.51) FEN1ALOX5APCDK8AXLPIK3CD
SCHEMBL30352947 0.75 CDK8 (0.54) FEN1ALOX5APCDK8AXLNUDT1
SCHEMBL20508757 0.73 PIK3CD (0.56) FEN1ALOX5APCDK8AXLPIK3CD
SCHEMBL28322681 0.72 ADORA3 (0.40) FEN1ALOX5APCDK8AXLPIK3CD
SCHEMBL845813 0.72 CDK8 (0.37) FEN1ALOX5APCDK8AXLPIK3CD
SCHEMBL5607323 0.72 RIPK1 (0.57) FEN1ALOX5APCDK8AXLRIPK1
SCHEMBL844875 0.71 MAPK1 (0.53) FEN1ALOX5APCDK8AXLPIK3CD
SCHEMBL17065175 0.70 MAP3K11 (0.46) CDK8PIK3CAULK1CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION (US) 2026-04-28 US disclosed
US-20230250100-A1 Pyrrolopyrimidines as CFTR Potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. 2023-08-10 US disclosed
US-20210171534-A1 Pyrrolopyrimidines as CFTR Potentiators CYSTIC FIBROSIS FOUNDATION 2021-06-10 US disclosed
US-20200017512-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS PFIZER INC. 2020-01-16 US disclosed
US-20190225621-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION 2019-07-25 US disclosed
US-10301315-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2019-05-28 US disclosed
US-20180141954-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171534-A1 Pyrrolopyrimidines as CFTR Potentiators CFTR, P2RX1, P2RX5 FEN1 1077/4885ALOX5AP 1248/4885CDK8 3284/4885
US-20200017512-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CFTR, P2RX1, P2RX5 FEN1 1077/4885ALOX5AP 1248/4885CDK8 3284/4885
US-20190225621-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CFTR, P2RX1, P2RX5 FEN1 1077/4885ALOX5AP 1248/4885CDK8 3284/4885
US-20230250100-A1 Pyrrolopyrimidines as CFTR Potentiators CFTR, P2RX1, P2RX5 FEN1 1077/4885ALOX5AP 1248/4885CDK8 3284/4885
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CFTR, CLCN2, SLC26A3 FEN1 2038/4885ALOX5AP 935/4885CDK8 4257/4885
US-10301315-B2 Pyrrolopyrimidines as CFTR potentiators CFTR, P2RX1, P2RX5 FEN1 1092/4885ALOX5AP 1468/4885CDK8 3437/4885
US-20180141954-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CFTR, P2RX1, P2RX5 FEN1 1092/4885ALOX5AP 1468/4885CDK8 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.